Advance in the Treatment of Pediatric Leukemia
The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are di...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Témata: | |
| On-line přístup: | ONIX_20220621_9783036541679_133 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869514805497298944 |
|---|---|
| collection | Directory of Open Access Books |
| description | The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML. |
| format | Online |
| id | doab-20.500.12854ir-84555 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-845552024-03-28T03:32:50Z Advance in the Treatment of Pediatric Leukemia Handgretinger, Rupert acute lymphoblastic leukemia pediatric advances diagnosis treatment immunotherapy bispecific T-cell engager (BiTE) BCP-ALL leukemia TRAIL antibody Fc-engineering xenograft CD19 juvenile myelomonocytic leukemia RAS signaling hematopoietic stem cell transplantation 5-azacitidine myelodysplastic/myeloproliferative disorders targeted therapy ADC antibody–drug conjugate pediatric leukemia ALL AML allogeneic stem cell transplantation acute myeloid leukemia minimal residual disease conditioning regimen alternative donors B-ALL DUX4 IKZF1 PAX5 Ph-like ZNF384 NUTM1 T-ALL NOTCH1 BCL11B transcriptome genome chronic myeloid leukemia CML tyrosine kinase inhibitor immunizations COVID-19 childhood acute lymphoblastic leukemia low-risk ALL risk-stratified treatment treatment related toxicity L-asparaginase acute pancreatitis polymorphism SNV ABCC4 CFTR other extramedullary relapse lymphoblastic leukemia children prognosis evolution of CAR T cells FDA-approved CAR products TcR versus CAR limitations and complications of CAR T cell therapy future directions of CAR T cell therapy n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML. 2022-06-21T08:42:07Z 2022-06-21T08:42:07Z 2022 book ONIX_20220621_9783036541679_133 9783036541679 9783036541686 https://directory.doabooks.org/handle/20.500.12854/84555 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/5539 https://mdpi.com/books/pdfview/book/5539 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-4168-6 10.3390/books978-3-0365-4168-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036541679 9783036541686 300 Basel open access |
| spellingShingle | acute lymphoblastic leukemia pediatric advances diagnosis treatment immunotherapy bispecific T-cell engager (BiTE) BCP-ALL leukemia TRAIL antibody Fc-engineering xenograft CD19 juvenile myelomonocytic leukemia RAS signaling hematopoietic stem cell transplantation 5-azacitidine myelodysplastic/myeloproliferative disorders targeted therapy ADC antibody–drug conjugate pediatric leukemia ALL AML allogeneic stem cell transplantation acute myeloid leukemia minimal residual disease conditioning regimen alternative donors B-ALL DUX4 IKZF1 PAX5 Ph-like ZNF384 NUTM1 T-ALL NOTCH1 BCL11B transcriptome genome chronic myeloid leukemia CML tyrosine kinase inhibitor immunizations COVID-19 childhood acute lymphoblastic leukemia low-risk ALL risk-stratified treatment treatment related toxicity L-asparaginase acute pancreatitis polymorphism SNV ABCC4 CFTR other extramedullary relapse lymphoblastic leukemia children prognosis evolution of CAR T cells FDA-approved CAR products TcR versus CAR limitations and complications of CAR T cell therapy future directions of CAR T cell therapy n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry Advance in the Treatment of Pediatric Leukemia |
| title | Advance in the Treatment of Pediatric Leukemia |
| title_full | Advance in the Treatment of Pediatric Leukemia |
| title_fullStr | Advance in the Treatment of Pediatric Leukemia |
| title_full_unstemmed | Advance in the Treatment of Pediatric Leukemia |
| title_short | Advance in the Treatment of Pediatric Leukemia |
| title_sort | advance in the treatment of pediatric leukemia |
| topic | acute lymphoblastic leukemia pediatric advances diagnosis treatment immunotherapy bispecific T-cell engager (BiTE) BCP-ALL leukemia TRAIL antibody Fc-engineering xenograft CD19 juvenile myelomonocytic leukemia RAS signaling hematopoietic stem cell transplantation 5-azacitidine myelodysplastic/myeloproliferative disorders targeted therapy ADC antibody–drug conjugate pediatric leukemia ALL AML allogeneic stem cell transplantation acute myeloid leukemia minimal residual disease conditioning regimen alternative donors B-ALL DUX4 IKZF1 PAX5 Ph-like ZNF384 NUTM1 T-ALL NOTCH1 BCL11B transcriptome genome chronic myeloid leukemia CML tyrosine kinase inhibitor immunizations COVID-19 childhood acute lymphoblastic leukemia low-risk ALL risk-stratified treatment treatment related toxicity L-asparaginase acute pancreatitis polymorphism SNV ABCC4 CFTR other extramedullary relapse lymphoblastic leukemia children prognosis evolution of CAR T cells FDA-approved CAR products TcR versus CAR limitations and complications of CAR T cell therapy future directions of CAR T cell therapy n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry |
| topic_facet | acute lymphoblastic leukemia pediatric advances diagnosis treatment immunotherapy bispecific T-cell engager (BiTE) BCP-ALL leukemia TRAIL antibody Fc-engineering xenograft CD19 juvenile myelomonocytic leukemia RAS signaling hematopoietic stem cell transplantation 5-azacitidine myelodysplastic/myeloproliferative disorders targeted therapy ADC antibody–drug conjugate pediatric leukemia ALL AML allogeneic stem cell transplantation acute myeloid leukemia minimal residual disease conditioning regimen alternative donors B-ALL DUX4 IKZF1 PAX5 Ph-like ZNF384 NUTM1 T-ALL NOTCH1 BCL11B transcriptome genome chronic myeloid leukemia CML tyrosine kinase inhibitor immunizations COVID-19 childhood acute lymphoblastic leukemia low-risk ALL risk-stratified treatment treatment related toxicity L-asparaginase acute pancreatitis polymorphism SNV ABCC4 CFTR other extramedullary relapse lymphoblastic leukemia children prognosis evolution of CAR T cells FDA-approved CAR products TcR versus CAR limitations and complications of CAR T cell therapy future directions of CAR T cell therapy n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry |
| url | ONIX_20220621_9783036541679_133 |